ES2731525T3 - Aminas terciarias para su uso en el tratamiento de trastornos cardíacos - Google Patents

Aminas terciarias para su uso en el tratamiento de trastornos cardíacos Download PDF

Info

Publication number
ES2731525T3
ES2731525T3 ES13723783T ES13723783T ES2731525T3 ES 2731525 T3 ES2731525 T3 ES 2731525T3 ES 13723783 T ES13723783 T ES 13723783T ES 13723783 T ES13723783 T ES 13723783T ES 2731525 T3 ES2731525 T3 ES 2731525T3
Authority
ES
Spain
Prior art keywords
compound
alkyl
denotes
mmol
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13723783T
Other languages
English (en)
Spanish (es)
Inventor
Kjetil Tasken
Birgitte Lygren
Ellen Østensen
Jo Klaveness
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitetet i Oslo
Original Assignee
Universitetet i Oslo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitetet i Oslo filed Critical Universitetet i Oslo
Application granted granted Critical
Publication of ES2731525T3 publication Critical patent/ES2731525T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/49—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring having at least two amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES13723783T 2012-05-18 2013-05-17 Aminas terciarias para su uso en el tratamiento de trastornos cardíacos Active ES2731525T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1208775.5A GB201208775D0 (en) 2012-05-18 2012-05-18 Chemical compounds
PCT/EP2013/060263 WO2013171332A2 (en) 2012-05-18 2013-05-17 Tertiary amines for use in the treatment of cardiac disorders

Publications (1)

Publication Number Publication Date
ES2731525T3 true ES2731525T3 (es) 2019-11-15

Family

ID=46546292

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13723783T Active ES2731525T3 (es) 2012-05-18 2013-05-17 Aminas terciarias para su uso en el tratamiento de trastornos cardíacos

Country Status (9)

Country Link
US (2) US9556111B2 (https=)
EP (1) EP2861568B1 (https=)
JP (1) JP6397398B2 (https=)
DK (1) DK2861568T3 (https=)
ES (1) ES2731525T3 (https=)
GB (1) GB201208775D0 (https=)
PL (1) PL2861568T3 (https=)
TR (1) TR201908770T4 (https=)
WO (1) WO2013171332A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201320506D0 (en) 2013-11-26 2014-01-01 Uni I Oslo Cyclic amino compounds for the use in the treatment of cardiac disorders
CN112174829B (zh) * 2020-10-27 2022-11-18 山东阳谷华泰化工股份有限公司 一种二苄胺的制备方法
WO2024119431A1 (en) * 2022-12-08 2024-06-13 Westlake University Apoe4 and lilrb3, variants and uses thereof
CN120271787B (zh) * 2025-06-05 2025-08-15 东莞市腾崴塑胶制品有限公司 一种低温聚氨酯海绵、制备方法及其化合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3634316A (en) * 1968-08-23 1972-01-11 Showa Denko Kk Sulfur-vulcanizable natural and synthetic rubbery polymers containing xylylene diamines as antiozonants
JPS496302B1 (https=) * 1968-09-30 1974-02-13
GB1263987A (en) * 1969-05-30 1972-02-16 Allen & Hanburys Ltd Phenethylamine derivatives
BE757601A (fr) * 1969-10-17 1971-04-16 Geigy Ag J R Derives basiques du pyrrole et medicaments renfermant de tels composes
DE2150293A1 (de) * 1971-10-08 1973-04-12 Hoechst Ag Fasern und faeden aus modifizierten synthetischen linearen polyestern mit verbesserter faerbbarkeit
NL8105170A (nl) * 1980-12-10 1982-07-01 Thomae Gmbh Dr K Nieuwe fenylalkylaminen, werkwijze ter bereiding daarvan en de toepassing daarvan als geneesmiddelen.
JPS62252746A (ja) * 1986-04-24 1987-11-04 Mitsubishi Chem Ind Ltd ３級アミンの製造方法
JPS63302364A (ja) * 1987-06-02 1988-12-09 Terumo Corp ペルオキシドフェニル化合物およびその製造法
US5871945A (en) 1994-11-23 1999-02-16 Icos Corporation Modulators of anchoring protein function
JPH08217731A (ja) * 1995-02-10 1996-08-27 Takeda Chem Ind Ltd キノン誘導体
DE19824922A1 (de) 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
JP2003524588A (ja) * 1998-06-18 2003-08-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ジェミナルに置換されたアミン
WO2000027852A1 (en) * 1998-11-10 2000-05-18 Meiji Seika Kaisha, Ltd. Novel imidazo[5,1-b]thiazole derivatives and fungicides containing the same as the active ingredient
US6723743B1 (en) 1999-09-28 2004-04-20 Neurogen Corporation High affinity small molecule C5a receptor modulators
US6958214B2 (en) 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
WO2003057673A1 (en) 2001-12-28 2003-07-17 Bayer Pharmaceuticals Corporation 1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
AU2003228809A1 (en) 2002-05-03 2003-11-17 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
PT2527315E (pt) * 2002-05-31 2014-06-24 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
CA2497254A1 (en) 2002-09-06 2004-03-18 Forschungsverbund Berlin E. V. Akap18 delta, a novel splicing variant of a protein kinase a anchor protein and the use of the same
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
ITGE20020104A1 (it) * 2002-11-22 2004-05-23 Fabrizio Parodi Composizioni polimeriche rapidamente riscaldabili
EP1601972A2 (en) 2003-03-07 2005-12-07 Sequenom, Inc. Association of polymorphic kinase anchor proteins with cardiac phenotypes and related methods
US8883160B2 (en) 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
DE102004031579B4 (de) 2004-06-29 2012-12-27 Forschungsverbund Berlin E.V. Peptide zur Inhibition der Interaktion von Proteinkinase A und Proteinkinase A-Ankerproteinen, diese umfassendes Nukleinsäuremolekül, Vektor, Wirtszelle, gegen diese gerichtetes Erkennungsmolekül, diese enthaltende pharmazeutische Zusammensetzung, diese enthaltender Kit und deren Verwendung
EP1771449A1 (en) 2004-07-21 2007-04-11 Pfizer Products Incorporated Histamine-3 receptor antagonists
GB0421356D0 (en) 2004-09-24 2004-10-27 Univ Oslo Inhibitors
GB0421355D0 (en) 2004-09-24 2004-10-27 Univ Oslo Inhibitors
WO2006122546A1 (de) 2005-05-18 2006-11-23 Forschungsverbund Berlin E.V. Nicht-peptidische inhibitoren der akap-pka-wechselwirkung
GB0518027D0 (en) 2005-09-05 2005-10-12 Birkeland Innovasjon As Compounds
EP1777230A1 (en) * 2005-10-19 2007-04-25 LG Chem Ltd. Multinuclear half metallocene catalyst and method for preparing syndiotactic polystyrene using the same
JP4216844B2 (ja) * 2005-10-31 2009-01-28 エルジー・ケム・リミテッド 新たな多核ハーフメタロセン触媒系及びそれを利用したシンジオタクチックポリスチレンの製造
CN100383112C (zh) * 2006-06-12 2008-04-23 清华大学 一种还原硝基苄胺化合物为氨基苄胺盐酸盐的方法
EP2098226A1 (de) 2008-03-06 2009-09-09 Forschungsverbund Berlin e.V. AKAP-PKA-Interaktionshemmer zur Anwendung in der Behandlung von Herzkrankheiten
WO2010010359A2 (en) * 2008-07-24 2010-01-28 Cilpa Limited A process for the preparation of cinacalcet and its salts
FR2940289B1 (fr) 2008-12-23 2014-09-12 Biopharmed Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas
HU1000676D0 (en) * 2010-12-17 2011-02-28 Pharmahungary 2000 Kft Inhibitors of matrix metalloproteinase, pharmaceutical compositions thereof and use of them for preventing and treating diseases where the activation of mmp is involved

Also Published As

Publication number Publication date
US9556111B2 (en) 2017-01-31
US9951033B2 (en) 2018-04-24
TR201908770T4 (tr) 2019-07-22
DK2861568T3 (da) 2019-06-17
EP2861568A2 (en) 2015-04-22
JP2015522537A (ja) 2015-08-06
JP6397398B2 (ja) 2018-09-26
EP2861568B1 (en) 2019-04-17
US20150133510A1 (en) 2015-05-14
WO2013171332A2 (en) 2013-11-21
WO2013171332A3 (en) 2014-04-17
GB201208775D0 (en) 2012-07-04
US20170158657A1 (en) 2017-06-08
PL2861568T3 (pl) 2019-11-29

Similar Documents

Publication Publication Date Title
CN1946398B (zh) 噻二唑二酮作为gsk-3抑制剂
JP6144873B2 (ja) Ｉｒｅ１、ｓｒｃ、及びａｂｌ活性を調節するための方法及び組成物
TW201742863A (zh) 靶向蛋白質之嵌合化合物、組合物、方法及其用途
US20210179577A1 (en) Aromatic sulfonamide derivatives for the treatment of ischemic stroke
JP6073377B2 (ja) Ｇｓｋ−３阻害剤としての新規チアジアゾリジンジオン
TW200911237A (en) Drug combinations for the treatment of duchenne muscular dystrophy
BRPI0713136A2 (pt) inibidores de akt (proteìna quinase b)
ES2897712T3 (es) Procedimientos para seleccionar inhibidores selectivos de fosfatasa y no selectivos de fosfatasa
ES2731525T3 (es) Aminas terciarias para su uso en el tratamiento de trastornos cardíacos
JP2026062757A (ja) コルヒチン誘導体の方法と使用
WO2017036318A1 (zh) 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
AU2018246341B2 (en) Compounds useful as inhibitors of ALCAT 1
BR112019012920A2 (pt) amidas aromáticas de ácido carboxílico como antagonistas do receptor b1 de bradicinina
CN105658634A (zh) 作为TCR-Nck相互作用的抑制剂的被醇盐取代的色烯衍生物
JP6534995B2 (ja) ＴＣＲ−Ｎｃｋ相互作用の阻害剤としてのクロメン誘導体
JP2021527692A (ja) Ｏａｔ３の阻害剤を用いた神経変性に関連する状態の処置方法
SA518391657B1 (ar) مشتقات بيريدين ثنائي الأمينو
ES2331451A1 (es) Inmunosupresor basado en la interrupcion de la interacion tcr-nck.
US9585880B2 (en) Cyclic amino compounds for use in the treatment of cardiac disorders
US11124490B2 (en) Autotaxin inhibitors
JP6269942B2 (ja) ｐ３８ＭＡＰキナーゼγおよび／またはδ阻害剤
BR112013024136A2 (pt) ligandos de receptor de opióide e métodos de usar e fabricar os mesmos
HK1225379B (zh) 作为tcr-nck相互作用的抑制剂的色烯衍生物
HK1163689B (en) Methods and compositions for modulating ire1, src, and abl activity